PAPER Korologou-Linden R, Kalsi J, Kafetsouli D, Olawale A, Iwata A, Wingfield D, Mummery D, Hayhoe B, Robinson O, Majeed A, Middleton LT
SEARCH RESULTS
335775 RESULTS
PAPER Zhou RZ, Wimo A, Winblad B
Editorial: On the 2024 Alzheimer's Association Criteria: Still Not Ready for Clinical Use.
J Prev Alzheimers Dis. 2024;11(4):895-896. PubMed.PAPER Jimenez-Maggiora GA, Schulz AP, Donohue MC, Qiu H, Jaiswal SN, Adegoke O, Gallardo R, Baryshnikava O, Rissman RA, Abdel-Latif S, Sperling RA, Aisen PS
Maximizing the Utility of Alzheimer's Disease Trial Data: Sharing of Baseline A4 and LEARN Data.
J Prev Alzheimers Dis. 2024;11(4):889-894. PubMed.PAPER Boyle R, Klinger HM, Shirzadi Z, Coughlan GT, Seto M, Properzi MJ, Townsend DL, Yuan Z, Scanlon C, Jutten RJ, Papp KV, Amariglio RE, Rentz DM, Chhatwal JP, Donohue MC, Sperling RA, Schultz AP, Buckley RF
Left Frontoparietal Control Network Connectivity Moderates the Effect of Amyloid on Cognitive Decline in Preclinical Alzheimer's Disease: The A4 Study.
J Prev Alzheimers Dis. 2024;11(4):881-888. PubMed.PAPER Raman R, Hussen K, Donohue MC, Ernstrom K, Holdridge KC, Langford O, Molina-Henry DP, Pierce AL, Sims JR, Smith A, Yaari R, Aisen PS, Sperling R, Grill JD
Pre-Randomization Predictors of Study Discontinuation in a Preclinical Alzheimer's Disease Randomized Controlled Trial.
J Prev Alzheimers Dis. 2024;11(4):874-880. PubMed.PAPER Yaari R, Holdridge KC, Mancini M, Rafii MS, Case M, Battioui C, Sims JR, Aisen PS, Sperling RA
Safety Profile of a Cognitively Unimpaired Older Population with Elevated Cerebral Amyloid in a 4.5-Year Clinical Trial.
J Prev Alzheimers Dis. 2024;11(4):857-868. PubMed.PAPER Papp KV, Maruff P, Rentz DM, Donohue MC, Liu A, Aisen PS, Sperling RA
Change in Digital Cognitive Test Performance between Solanezumab and Placebo Groups in Preclinical Alzheimer's Disease: Secondary Analyses from the A4 Study.
J Prev Alzheimers Dis. 2024;11(4):846-856. PubMed.PAPER Amariglio RE, Grill JD, Rentz DM, Marshall GA, Donohue MC, Liu A, Aisen PS, Sperling RA
Longitudinal Trajectories of the Cognitive Function Index in the A4 Study.
J Prev Alzheimers Dis. 2024;11(4):838-845. PubMed.PAPER Molina-Henry D, Langford O, Donohue MC, Raman R, Aisen P, Johnson KA, Rissman RA, Sperling R
Relationship between Plasma P-Tau217 and Amyloid PET in Racial and Ethnic Underrepresented Groups (RE-URG) Compared with Non RE-URG in LEARN and A4.
J Prev Alzheimers Dis. 2024;11(4):831-837. PubMed.PAPER Rissman RA, Donohue MC, Langford O, Raman R, Abdel-Latif S, Yaari R, Holdridge KC, Sims JR, Molina-Henry D, Jimenez-Maggiora G, Johnson KA, Aisen PS, Sperling RA
Longitudinal Phospho-tau217 Predicts Amyloid Positron Emission Tomography in Asymptomatic Alzheimer's Disease.
J Prev Alzheimers Dis. 2024;11(4):823-830. PubMed.PAPER Rentz DM, Rosenberg PB, Sperling RA, Donohue MC, Raman R, Liu A, Aisen PS
Characterizing Clinical Progression in Cognitively Unimpaired Older Individuals with Brain Amyloid: Results from the A4 Study.
J Prev Alzheimers Dis. 2024;11(4):814-822. PubMed.PAPER Aisen P, Sperling R
Editorial: Introduction to the Special Issue on the A4 Study.
J Prev Alzheimers Dis. 2024;11(4):801. PubMed.Joanne Caverley
RSL LifecareSydney, Australia
PAPER Schneider AL, Pike JR, Elser H, Coresh J, Mosley TH, Diaz-Arrastia R, Gottesman RF
Traumatic brain injury and cognitive change over 30 years among community-dwelling older adults.
Alzheimers Dement. 2024 Jul 5; PubMed.Postdoctoral Researcher, Population Neuroscience of Aging, Alzheimer’s Disease and Age-Related Dementia
JOB 2024-07-24 Employer University of Pittsburgh Description The PNA Training Program will train highly talented individuals to pursue successful independent research in the etiology of Alzheimer’s disease and other age-related dementia (ADRD). The program offers two po
Current Filters
No filters selected